Genomic Health Inc. Stock Upgraded (GHDX)

NEW YORK (TheStreet) -- Genomic Health (Nasdaq:GHDX) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Highlights from the ratings report include:

• GHDX's revenue growth has slightly outpaced the industry average of 7.4%. Since the same quarter one year prior, revenues rose by 13.3%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
• GHDX has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 5.96, which clearly demonstrates the ability to cover short-term cash needs.
• The gross profit margin for GENOMIC HEALTH INC is currently very high, coming in at 86.60%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, GHDX's net profit margin of 3.10% significantly trails the industry average.
• Compared to its closing price of one year ago, GHDX's share price has jumped by 47.70%, exceeding the performance of the broader market during that same time frame. We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its industry. The other strengths this company shows, however, justify the higher price levels.
• GENOMIC HEALTH INC's earnings per share declined by 25.0% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, GENOMIC HEALTH INC increased its bottom line by earning $0.25 versus $0.14 in the prior year. For the next year, the market is expecting a contraction of 29.6% in earnings ($0.18 versus $0.25).

Genomic Health, Inc., a molecular diagnostics company, engages in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. The company has a P/E ratio of 134.1, above the average health services industry P/E ratio of 108 and above the S&P 500 P/E ratio of 17.7. Genomic Health has a market cap of $941.5 million and is part of the health care sector and health services industry. Shares are up 42.7% year to date as of the close of trading on Monday.

You can view the full Genomic Health Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

For more information on Genomic Health Inc. click any of the following:

• Genomic Health Inc. Stock Price

• Genomic Health Inc. Analyst Ratings

• Genomic Health Inc. Key Stats & Profile

• Genomic Health Inc. Earnings

• Genomic Health Inc. Ratio Comparison

• Genomic Health Inc. Growth Rates

• Genomic Health Inc. Balance Sheet

• Genomic Health Inc. Cash Flow

• Genomic Health Inc. Income Statement